Decrease in the oral bioavailability of dabigatran etexilate after co-medication with rifampicin

British Journal of Clinical Pharmacology

Volumn 74, Issue 3, 2012, Pages 490-500

  Härtter, Sebastian ^a   Koenen Bergmann, Michael ^a   Sharma, Ashish ^a   Nehmiz, Gerhard ^a   Lemke, Ute ^a   Timmer, Wolfgang ^b   Reilly, Paul A ^c  

^a BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^b CRS Mannheim GmbH   (Germany)

^c BOEHRINGER INGELHEIM PHARMACEUTICALS INC   (United States)

Author keywords

Dabigatran etexilate; Drug interaction; P glycoprotein; Rifampicin

Indexed keywords

BIBR 1087 SE; BIBR 951 BS; DABIGATRAN ETEXILATE; DRUG METABOLITE; RIFAMPICIN; UNCLASSIFIED DRUG;

ADULT; AREA UNDER THE CURVE; ARTICLE; CLINICAL TRIAL; DIZZINESS; DRUG BIOAVAILABILITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG EXPOSURE; DRUG HALF LIFE; DRUG SAFETY; DRUG TOLERABILITY; ELECTROCARDIOGRAM; EVENING DOSAGE; FATIGUE; FEMALE; HEADACHE; HUMAN; HUMAN EXPERIMENT; HYPERHIDROSIS; MALE; MORNING DOSAGE; NAUSEA; NORMAL HUMAN; OROPHARYNX PAIN; PRIORITY JOURNAL; SIDE EFFECT; SINGLE DRUG DOSE; VERTIGO; VITAL SIGN; VOMITING;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; BENZIMIDAZOLES; BIOLOGICAL AVAILABILITY; DRUG INTERACTIONS; ENZYME INHIBITORS; FEMALE; GLUCURONIDES; HALF-LIFE; HUMANS; MALE; PRODRUGS; PYRIDINES; RIFAMPIN; YOUNG ADULT;

EID: 84864808150     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04218.x     Document Type: Article

References (32)

1. Stangier J, Eriksson BI, Dahl OE, Ahnfelt L, Nehmiz G, Stähle H, Rathgen K, Svärd R. Pharmacokinetic profile of the oral direct thrombin inhibitor dabagitran etexilate in healthy volunteers and patients undergoing total hip replacement. J Clin Pharmacol 2005; 45: 555-63.
2. Blech S, Ebner T, Ludwig-Schwellinger E, Stangier J, Roth W. The metabolism and disposition of the oral direct thrombin inhibitor, dabigatran, in humans. Drug Metab Dispos 2008; 36: 386-99.
3. Stangier J, Rathgen K, Stähle H, Gansser D, Roth W. The pharmacokinetics, pharmacodynamics and tolerability of dabigatran, a new oral direct thrombin inhibitor in healthy male subjects. Br J Clin Pharmacol 2007; 64: 292-303.
4. Stangier J. Clinical pharmacokinetics and pharmacodynamics of the oral direct thrombin inhibitor dabigatran etexilate. Clin Pharmacokinet 2008; 47: 285-95.
5. Stangier J, Stähle H, Rathgen K, Fuhr R. Pharmacokinetics and pharmacodynamics of the direct oral thrombin inhibitor dabigatran in healthy elderly subjects. Clin Pharmacokinet 2008; 47: 47-59.
6. Stangier J, Rathgen K, Stähle H, Mazur D. Influence of renal impairment on the pharmacokinetics and pharmacodynamics of oral dabigatran etexilate: an open-label, parallel-group, single-centre study. Clin Pharmacokinet 2010; 49: 259-68.
7. Boehringer Ingelheim, Burlington, ON. Pradax™ Product Monograph [Internet]. 2012. Available at http://webprod3.hc-sc.gc.ca/dpd-bdpp/info.do?lang=eng&code=84384 (last accessed 28 February 2012).
8. FDA [Internet]. Pradaxa label. 2010. Available at http://www.accessdata.fda.gov/drugsatfda_docs/label/2010/022512s000lbl.pdf (last accessed 6 April 2011).
9. Biotech Pharma News [Internet]. Boehringer Ingelheim: PRAZAXA (dabigatran etexilate) approved in Japan for stroke prevention in atrial fibrillation. 2011. Available at http://www.biotechpharmanews.com/news/37-jan-2011/634-boehringer-ingelheim-prazaxa-dabigatran-etexilate-approved-in-japan-for-stroke-prevention-in-atrial-fibrillation.html (last accessed 28 February 2012).
10. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Kälebo P, Christiansen AV, Hantel S, Hettiarachchi R, Schnee J, Büller HR (RE-MODEL Study Group). Oral dabigatran etexilate vs. subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial. J Thromb Haemost 2007; 5: 2178-85.
11. Eriksson BI, Dahl OE, Rosencher N, Kurth AA, van Dijk CN, Frostick SP, Prins MH, Hettiaracchi R, Hantel S, Schnee J, Büller HR. Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial. Lancet 2007; 370: 949-56.
12. Eriksson B, Dahl OE, Huo MH, Kurth AA, Hantel S, Hermansson K, Prins MH, Hettiarachchi R, Hantel S, Schnee J, Büller HR (RE-NOVATE Study Group). for the RE-NOVATE II Study Group: oral dabigatran versus enoxaparin for thromboprophylaxis after primary total hip arthroplasty (RE-NOVATE II). Thromb Haemost 2011; 105: 721-9.
13. Connolly SJ, Ezekowitz MD, Yusuf S, Eikelboom J, Oldgren J, Parekh A, Pogue J, Reilly PA, Themeles E, Varrone J, Wang S, Alings M, Xavier D, Zhu J, Diaz R, Lewis BS, Darius H, Diener HC, Joyner CD, Wallentin L (RE-LY Steering Committee and Investigators). Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-51.
14. Stangier J, Stähle H, Rathgen K, Reseski K, Kornicke T. Coadministration of the oral direct thrombin inhibitor dabigatran etexilate and diclofenac has little impact on the pharmacokinetics of either drug. J Thromb Haemost 2007; 5: (Suppl. 2). Abstract P-W-677.
15. Stangier J, Stähle H, Rathgen K, Reseski K, Körnicke T. No interaction of the oral direct thrombin inhibitor dabigatran etexilate and digoxin. J Thromb Haemost 2007; 5: (Suppl. 2). Abstract P-W-672.
16. Stangier J, Rathgen K, Stähle H, Reseski K, Körnicke T, Roth W. Coadministration of dabigatran etexilate and atorvastatin: assessment of potential impact on pharmacokinetics and pharmacodynamics. Am J Cardiovasc Drugs 2009; 9: 59-68.
17. Boehringer Ingelheim, Ridgefield, CT. Pradaxa® US prescribing information [Internet]. 2012. Available at http://bidocs.boehringer-ingelheim.com/BIWebAccess/ViewServlet.ser?docBase=renetnt&folderPath=/Prescribing%20Information/PIs/Pradaxa/Pradaxa.pdf (last accessed 28 February 2012).
18. Ufer M. Comparative efficacy and safety of the novel oral anticoagulants dabigatran, rivaroxaban and apixaban in preclinical and clinical development. Thromb Haemost 2010; 103: 572-85.
19. Backman JT, Olkkola KT, Neuvonen PJ. Rifampin drastically reduces plasma concentrations and effects of oral midazolam. Clin Pharmacol Ther 1996; 59: 7-13.
20. Backman JT, Kivisto KT, Olkkola KT, Neuvonen PJ. The area under the plasma concentration-time curve for oral midazolam is 400-fold larger during treatment with itraconazole than with rifampicin. Eur J Clin Pharmacol 1998; 54: 53-8.
21. Galteau MM, Shamsa F. Urinary 6beta-hydroxycortisol: a validated test for evaluating drug induction or drug inhibition mediated through CYP3A in humans and in animals. Eur J Clin Pharmacol 2003; 59: 713-33.
22. Pocock SJ, Geller NL, Tsiatis AA. The analysis of multiple endpoints in clinical trials. Biometrics 1987; 43: 487-98.
23. Advisory Committee Briefing Document [Internet]. Dabigatran etexilate. Boehringer Ingelheim; 2010. Available at http://www.fda.gov/downloads/AdvisoryCommittees/CommitteesMeetingMaterials/Drugs/CardiovascularandRenalDrugsAdvisoryCommittee/UCM226009.pdf (last accessed 4 April 2011).
24. Tran JQ, Kovacs SJ, McIntosh TS, Davis HM, Martin DE. Morning spot and 24-hour urinary 6 beta-hydroxycortisol to cortisol ratios: intraindividual variability and correlation under basal conditions and conditions of CYP3A4 induction. J Clin Pharmacol 1999; 39: 487-94.
25. Niemi M, Backman JT, Fromm MF, Neuvonen PJ, Kivisto KT. Pharmacokinetic interactions with rifampicin: clinical relevance. Clin Pharmacokinet 2003; 42: 819-50.
26. Gupta A, Mugundu GM, Desai PB, Thummel KE, Unadkat JD. Intestinal human colon adenocarcinoma cell line LS180 is an excellent model to study pregnane X receptor, but not constitutive androstane receptor, mediated CYP3A4 and multidrug resistance transporter 1 induction: studies with anti-human immunodeficiency virus protease inhibitors. Drug Metab Dispos 2008; 36: 1172-80.
27. Greiner B, Eichelbaum M, Fritz P, Kreichgauer HP, von Richter O, Zundler J, Kroemer HK. The role of intestinal P-glycoprotein in the interaction of digoxin and rifampin. J Clin Invest 1999; 104: 147-53.
28. Tapaninen T, Neuvonen PJ, Niemi M. Rifampicin reduces the plasma concentrations and the renin-inhibiting effect of aliskiren. Eur J Clin Pharmacol 2010; 66: 497-502.
29. Kishimoto W, Ishiguro N, Saito A, Ebner T, Haertter S, Igarashi T. Characterization of drug transporters involved in the disposition of dabigatran etexilate and its active form, dabigatran. 9th Int Mtg Int Soc Study Xenobiotics (ISSX), Istanbul, 4-8 Sep 2010. Drug Metab Rev 2010; 42: 293. Abstr P469.
30. Moualla H, Garcia D. Vitamin K antagonists - current concepts and challenges. Thromb Res 2011; 128: 210-15.
31. Deloughery TG. Practical aspects of the oral new anticoagulants. Am J Hematol 2011; 86: 586-90.
32. Boehringer Ingelheim, Ingelheim. Pradaxa® summary of product characteristics [Internet]. 2011. Available at http://www.medicines.org.uk/emc/medicine/20760/SPC/Pradaxa+110+mg+hard+capsules (last accessed 28 February 2012).